Levofolinate Yakult is a supportive medication used in various oncological therapeutic contexts.

This medication is primarily used to help manage toxicity risks following high-dose anti-folate cancer treatments, and is relevant for easing symptom-related distress when used with companion drugs, such as 5-fluorouracil, in the treatment of various advanced solid tumors. It is applied in addressing conditions marked by increased physiological stress due to severe systemic toxicity.

This supportive use helps address symptom clusters related to heightened physiological activity, such as pronounced diarrhea, painful mouth inflammation, and risks associated with decreased blood cell counts (myelosuppression). Levofolinate Yakult is commonly used across conditions presenting with acute episodes where patients experience heightened symptoms, including metastatic colorectal cancer, unresectable gastric cancer, and specific high-dose methotrexate protocols for osteosarcoma and acute leukemias. It assists with maintaining functional stability during phases when symptoms become more noticeable and could interfere with continuity of care.

“This medication plays a role in managing symptoms that create noticeable physiological strain during high-intensity treatments.”

Quick Fact: Relief for Severe Toxicity Risk The medication helps support patients during episodes of heightened discomfort by addressing risks associated with systemic imbalance in the gastrointestinal tract and blood-forming tissues.

Regulatory References

1. FDA DailyMed official label for Levoleucovorin

Eligibility for Levofolinate Yakult

Official regulatory documentation establishes strict rules for who can and cannot use Levofolinate Yakult (levoleucovorin), primarily based on hypersensitivity, deficiency states, and concurrent conditions.

Contraindicated Populations

Classification	Population	Status
Absolute Contraindication	Patients with known hypersensitivity or allergic reactions to folic acid or folinic acid products.	Must not use
Limitation of Use	Patients with pernicious anemia or other megaloblastic anemias secondary to Vitamin B12 deficiency.	Not approved; use risks progression of neurological damage.

Age and Condition-Specific Rules

Population	Regulatory Status	Constraint
Adults & Children	Use is established	Approved for rescue after high-dose methotrexate (MTX) and treatment of antagonist overdosage.
Pediatric Patients	Use is not established	Not approved for use in combination with 5-fluorouracil (5-FU) for metastatic colorectal cancer.
Older Adults (65+)	Use is permitted	At increased risk of severe toxicity (e.g., gastrointestinal issues) when treated with 5-FU combination therapy.
Pregnant/Nursing	Use is restricted	Unknown fetal harm; given only if clearly needed in pregnancy. Unknown whether excreted in human milk.
GI Toxicity	Use is conditional	Combination therapy with 5-FU must not be initiated or continued until severe gastrointestinal symptoms (diarrhea, stomatitis) have fully resolved.

This structure defines the authorized patient groups and critical prohibitions based on regulatory standards, ensuring use aligns with established safety profiles.

Officially documented interaction patterns for Disodium Levofolinate focus on pharmacodynamic effects with specific chemotherapeutic agents and alterations in the exposure of certain co-administered medicines. All interaction information is based on government regulatory labeling.

Pharmacodynamic Alterations

Co-administration with other medicinal products may result in two primary pharmacodynamic outcomes:

• Augmentation: The product is officially documented to augment the cytotoxic effects and resulting toxicity of fluoropyrimidines, such as 5-fluorouracil (5-FU). This effect is an intended feature of specific treatment protocols.
• Interference: Levofolinate is documented to interfere with and diminish the activity of folic acid antagonists, including anti-folate chemotherapeutics like Methotrexate and anti-infectives such as Trimethoprim or Pyrimethamine. This interference is the basis of its use in rescue protocols.

Exposure-Modifying Interactions

Co-administration with certain agents may alter their concentration in the bloodstream. Regulatory documentation states that use with antiepileptic agents, specifically Phenobarbital, Phenytoin, or Primidone, results in a reduction in the plasma concentration of these anticonvulsants.

Administration Constraints

Interactions with anti-folate medicinal products impose strict procedural requirements. Administration must adhere to the mandatory, time-based constraints defined in high-dose Methotrexate rescue protocols to ensure the intended neutralization of Methotrexate's effect is achieved at the correct phase. No documented interactions are reported with food, alcohol, or herbal products. No population-specific interaction adjustments are mandated in official labeling.

The mechanism of Disodium Levofolinate (Levoleucovorin) is centered on its role as a reduced folate derivative, which acts as a metabolic modulator in pathways governing DNA synthesis, achieving both cellular rescue and potentiation.

---

Modulating Thymidylate Synthase Activity

This mechanistic domain involves the specific interaction of the drug’s active form, 5,10-methylenetetrahydrofolate (5,10-mTHF), with the key DNA precursor enzyme, Thymidylate Synthase (TS). The 5,10-mTHF stabilizes the irreversible bond between TS and co-administered anti-pyrimidine agents (such as FdUMP) . This interaction potentiates the sustained metabolic blockade of pyrimidine synthesis, contributing to a prolonged DNA synthesis arrest in target cell populations.

---

Folate Co-factor Rescue and Metabolic Bypass

Levofolinate provides a direct source of essential folate co-factors, which is the basis for its cellular rescue mechanism. By supplying active folates without requiring the compromised Dihydrofolate Reductase (DHFR) pathway, the mechanism creates a metabolic bypass. This metabolic bypass restores fundamental DNA repair and synthesis processes in healthy, non-target cells, resulting in restored metabolic function and differential physiological response in these populations.

The use of Levofolinate (Disodium Levofolinate) is strictly limited to Intravenous (IV) administration as an infusion or injection. The solution requires dilution prior to infusion, typically with 0.9% Sodium Chloride or 5% Dextrose to a required concentration, and must not be mixed with other agents.

Dosage is dictated by the specific protocol. For High-Dose Methotrexate (MTX) rescue, the standard initial dose is 7.5 mg, administered every 6 hours, commencing 24 hours after the start of the MTX infusion. This regimen is applicable to both adult and pediatric patients. The course must be extended until the patient's serum MTX level is confirmed to be below 0.05 micromolar.

When Levofolinate is used to enhance the activity of 5-Fluorouracil (5-FU), the described dose ranges from 10 mg/m^2 (bolus) to 100 mg/m^2 (infusion), typically administered in cyclic patterns. Rescue protocols include concurrent hydration and procedural measures to ensure urinary pH maintenance. Dosing requires immediate upward adjustment (e.g., increased dose and frequency to every 3 hours) if laboratory monitoring shows delayed MTX elimination or signs of renal injury.

Research Evidence / Overview of Studies for Levofolinate Yakult

Evidence for Use as a Cellular Rescue Agent

Levofolinate Yakult was studied for its role in protocols that address the potential for severe side effects following high-dose Methotrexate (HDMTX) treatments, which are used for conditions like osteosarcoma and certain acute leukemias. Research has explored the use of non-randomized controlled trials and case reports to observe patterns related to the medicine’s supportive function. The core of this evidence examined the ability to help clear Methotrexate from the body and monitored the occurrence of outcomes related to acute systemic toxicity.

The research describes patterns in which Levofolinate administration was associated with Methotrexate levels returning toward target safety thresholds required for use during the acute phase of therapy. This supportive approach was observed in studies that monitored outcomes related to acute systemic toxicity, such as severe myelosuppression (a drop in blood cell counts) and stomatitis (mouth soreness). These findings describe patterns observed in studies involving primarily children and young adults undergoing these high-intensity treatment cycles.

Evidence for Use as a Chemotherapy Modulator

Levofolinate Yakult was also studied for its application alongside the anti-cancer drug 5-fluorouracil (5-FU). This research focused on its potential role in chemotherapy protocols and monitoring certain side effects in patients with advanced metastatic colorectal cancer. The supporting evidence is primarily derived from Randomized Phase 3 Clinical Trials (RCTs) and subsequent systematic reviews.

These trials monitored important survival outcomes for patients, including overall survival and progression-free survival, as well as the objective response rate of tumors. Furthermore, studies tracked outcomes related to physical discomfort, specifically the occurrence and intensity of gastrointestinal toxicities (like diarrhea and painful mouth inflammation) which are linked to inflammatory or irritative states caused by 5-FU. Findings described the combination of Levofolinate and 5-FU as a documented reference regimen in oncology, and research highlights changes measured in patient populations with advanced disease.

What is Still Uncertain About the Research Evidence

Despite the high volume of research supporting the established uses of Levofolinate, certainty remains low in several key areas. The evidence base for chemotherapy modulation often treats the pure L-isomer and the racemic mixture as clinically interchangeable; thus, comparative evidence is lacking to explore if one formulation is associated with distinct clinical outcomes compared to the other. Additionally, subgroup findings are uncertain for specific populations, such as elderly patients or those with multiple chronic illnesses, as these groups were often excluded from the foundational clinical trials.

Key Studies & References

1. FDA Label and Package Insert for Levoleucovorin Calcium (Official DailyMed Monograph)
2. WHO Anatomical Therapeutic Chemical (ATC) Classification: V03AF04 (Levoleucovorin)

Common questions about Levofolinate Yakult (FAQ)

Q: Does Levofolinate Yakult have other uses besides cancer treatment protocols?

Official documentation describes the medicine’s role as a rescue agent for high-dose methotrexate (MTX) treatment. This is a primary use condition established in regulatory standards. It is also used in specific protocols to counteract the effects of other drugs that function as folic acid antagonists.

Q: Why is the drug named Levofolinate Yakult?

This name refers to the product's composition and its manufacturer. Levofolinate is the name of the active, pure L-isomer of the medicine, also known as levoleucovorin. Yakult is the name of the company, Yakult Honsha Co., Ltd., which holds the marketing authorization for this specific formulation.

Q: Is it common to experience skin reactions or rash with this medicine?

Official regulatory sources list general skin reactions, such as rash, pruritus (itching), and urticaria (hives), as documented adverse reactions. The frequency of these specific reactions can vary widely depending on the patient's overall treatment regimen. Patients should always discuss any severe reactions with their prescribing healthcare team.

Q: Can Levofolinate Yakult be administered to patients with kidney or liver impairment?

The official product information notes that the medicine’s use requires careful monitoring, particularly if there are signs of delayed methotrexate clearance or acute renal injury. Furthermore, regulatory safety information documents the potential for serious hepatic (liver) adverse reactions that have occurred in some patients.

Q: What does 'clinical evidence' mean in the context of this drug?

Clinical evidence refers to the comprehensive data collected during controlled studies that regulatory bodies rely on for approval. This evidence includes information gathered from trials, such as Randomized Phase 3 Trials, and systematic reviews. These studies measure important patient outcomes, including survival rates and the frequency of specific side effects.

Q: Is it normal to feel no different immediately after receiving Levofolinate Yakult?

Yes, according to official information, this is an expected experience. The medicine acts at a cellular and metabolic level as a rescue agent and modulator. Since its purpose is not to produce a direct physical sensation, it is common not to feel subjectively different immediately after the administration.

Q: How long do side effects from Levofolinate Yakult generally take to appear?

The timing of any side effects is tied directly to the specific treatment protocol being used. For rescue protocols, effects are monitored immediately in the acute phase. In combination regimens, the onset of toxicities often follows the cyclic administration schedule of the co-administered chemotherapy.

Q: Where can I find publicly available data from the research trials for this drug?

Official trial information is managed and maintained by government authorities. You can find publicly available data through regulatory sources, such as the National Institutes of Health's clinical trial database (ClinicalTrials.gov) or the drug’s official assessment reports published by the Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

Storage and Disposal of Levofolinate Yakult Solution

Official regulatory information defines the specific conditions for storing and disposing of Levofolinate Yakult (Disodium Levofolinate Solution).

Storage Component	Requirement
Unopened Vials	Store below 25 C and keep in the outer carton to protect from light. The product must not be refrigerated or frozen.
Stability After Dilution	From a microbiological view, the solution should be used immediately. Storage is permitted for a maximum of 24 hours at 2 C – 8 C only if prepared under controlled aseptic conditions.
Child Safety	The medicine must be kept out of the sight and reach of children.
Disposal	Any unused solution must be discarded. Disposal of the medicine and waste material must be in accordance with local requirements and must not be done through household waste or wastewater.